公开(公告)号：US20210210244A1

公开(公告)日：2021-07-08

申请号：US16980617

申请日：2019-03-01

Applicant: OSAKA UNIVERSITY

Inventor： Atsushi SHINOHARA ,  Atsushi TOYOSHIMA ,  Zijian ZHANG ,  Akimitsu KANDA ,  Soichiro ICHIMURA

IPC: G21G1/00 ,  G21G4/08

Abstract: There is provided a radionuclide manufacturing system, a computer-readable storage medium storing a radionuclide manufacturing program, a radionuclide manufacturing method, and a terminal device for more stably manufacturing a radionuclide.
A radionuclide manufacturing system includes: a heating unit configured to internally house a target holding a radionuclide; a gas supply unit; an adsorption unit configured to adsorb the radionuclide; a solvent supply unit; a storage unit configured to store a predetermined instruction; and a control unit configured to control the heating unit to heat the target at a temperature at which the radionuclide held in the target is allowed to volatilize, to control the gas supply unit to supply the carrier gas to the heating unit in order to transport the radionuclide volatilized in the heating unit to the adsorption unit, and to control the solvent supply unit in order to supply a solvent for eluting the radionuclide adsorbed to the adsorption unit to the adsorption unit based on the instruction.

公开(公告)号：US20230233705A1

公开(公告)日：2023-07-27

申请号：US17925099

申请日：2021-05-14

Applicant: OSAKA UNIVERSITY

Inventor： Hiroki KATO ,  Koichi FUKASE ,  Kazuya KABAYAMA ,  Atsushi SHIMOYAMA ,  Yuichiro KADONAGA ,  Atsushi TOYOSHIMA ,  Atsushi SHINOHARA ,  Yasufumi KANEDA ,  Tomoyuki NISHIKAWA

IPC: A61K47/69 ,  A61P35/00 ,  A61P25/00 ,  A61K41/00 ,  A61P1/18

CPC classification number: A61K47/6923 ,  A61K47/6935 ,  A61P35/00 ,  A61P25/00 ,  A61K41/0038 ,  A61P1/18

Abstract: The present invention relates to a gold nanoparticle-containing medicine, and a treatment of a proliferative disease using the medicine. The present invention also relates to a gold nanoparticle-containing medicine that is bound to an alpha radioactive nucleus, and a treatment of a proliferative disease using the medicine.

公开(公告)号：US20200290872A1

公开(公告)日：2020-09-17

申请号：US16770403

申请日：2018-12-07

Applicant: OSAKA UNIVERSITY

Inventor： Atsushi SHINOHARA ,  Atsushi TOYOSHIMA ,  Takashi YOSHIMURA ,  Akimitsu KANDA

IPC: C01B7/00 ,  G21G1/00

Abstract: Provided is a method capable of separating and purifying astatine-211 in a high yield and dissolving same in a solution. A method for producing astatine-211, including a step of irradiating α ray to bismuth to produce astatine-211 in the bismuth, and a step of distilling the bismuth that received α ray irradiation with a carrier gas containing an inert gas, O2 and H2O to separate and purify astatine-211, and dissolving the astatine-211 in a solution.

公开(公告)号：US20240293586A1

公开(公告)日：2024-09-05

申请号：US18293488

申请日：2022-07-29

Applicant: OSAKA UNIVERSITY

Inventor： Yoshifumi SHIRAKAMI ,  Kazuko KANEDA ,  Yuichiro KADONAGA ,  Tadashi WATABE ,  Atsushi TOYOSHIMA ,  Koichi FUKASE ,  Taku YOSHIYA

IPC: A61K51/08 ,  A61P35/00

CPC classification number: A61K51/088 ,  A61P35/00 ,  A61K2121/00

Abstract: The aims of the present invention are to provide an agent that binds specifically to PSMA, is effective in the treatment and diagnosis of tumors or cancers expressing PSMA, for example, the treatment and diagnosis of prostate cancer, especially castration-resistant prostate cancer (CRPC), further especially metastatic castration-resistant prostate cancer (mCRPC), and does not exhibit side effects due to accumulation in the kidney or salivary glands. The present invention provides a radiolabeled compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:




wherein each symbol is as defined in the description.

公开(公告)号：US20240124496A1

公开(公告)日：2024-04-18

申请号：US18551674

申请日：2022-03-24

Applicant: OSAKA UNIVERSITY

Inventor： Yoshifumi SHIRAKAMI ,  Kazuko KANEDA ,  Yuichiro KADONAGA ,  Tadashi WATABE ,  Atsushi TOYOSHIMA ,  Koichi FUKASE ,  Atsushi SHINOHARA ,  Toshio YAMANAKA ,  Yutaka KONDOH

IPC: C07F5/02 ,  B01J31/22 ,  B01J31/24 ,  C07B59/00 ,  C07C227/16 ,  C07F13/00

CPC classification number: C07F5/025 ,  B01J31/2295 ,  B01J31/2409 ,  C07B59/00 ,  C07C227/16 ,  C07F13/00 ,  B01J2231/40 ,  B01J2531/004 ,  B01J2531/824 ,  B01J2531/842 ,  C07B2200/05

Abstract: The invention provides a method for producing radiolabeled tyrosine derivatives with good purity and stability, by a safe method suitable for industrial production of pharmaceuticals. The invention relates to a method for producing Compound (5) and Radiolabeled Compound (6) as follows:




wherein each symbol is as defined in the description.